Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9BNF

SARS-CoV-2 spike HexaPro protein in complex with T5A trimeric antagonist

Summary for 9BNF
Entry DOI10.2210/pdb9bnf/pdb
EMDB information44726
DescriptorCollagen alpha-1(XVIII) chain,Processed angiotensin-converting enzyme 2, Spike glycoprotein, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (4 entities in total)
Functional Keywordstrimeric antagonist sars-cov-2 complex, viral protein-antagonist complex, viral protein/antagonist
Biological sourceHomo sapiens (human)
More
Total number of polymer chains6
Total formula weight676059.43
Authors
Young, T. (deposition date: 2024-05-02, release date: 2025-08-27, Last modification date: 2025-10-29)
Primary citationGonzales, J.,Young, T.,Choi, H.,Park, M.,Jewel, Y.,Fan, C.,Purohit, R.,Bjorkman, P.J.,Williams, J.C.
Development of an ultrahigh affinity, trimeric ACE2 biologic as a universal SARS-CoV-2 antagonist.
Commun Biol, 8:1428-1428, 2025
Cited by
PubMed Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the COVID-19 pandemic, utilizes membrane-bound, angiotensin-converting enzyme II (ACE2) for internalization and infection. We describe the development of a biologic that takes advantage of the proximity of the N-terminus of bound ACE2 to the three-fold symmetry axis of the spike protein to create an ultrapotent, trivalent ACE2 entry antagonist. Distinct disulfide bonds were added to enhance serum stability and a single point mutation was introduced to eliminate enzymatic activity. Through surface plasmon resonance, pseudovirus neutralization assays, and single-particle cryo-electron microscopy, we show this antagonist binds to and inhibits SARS-CoV-2 variants. We further show the antagonist binds to and inhibits a 2003 SARS-CoV-1 strain. Collectively, structural insight has allowed us to design a universal trivalent antagonist against all variants of SARS-CoV-2 tested, suggesting it will be active against the emergence of future mutants.
PubMed: 41053501
DOI: 10.1038/s42003-025-08819-w
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (3.33 Å)
Structure validation

247947

PDB entries from 2026-01-21

PDB statisticsPDBj update infoContact PDBjnumon